Overview

Bowel Function After Minimally Invasive Urogynecologic Surgery

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of this study is to assess the effect of a standardized postoperative bowel regimen of over-the-counter medications in subjects undergoing minimally invasive urogynecologic surgery.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
University of Rochester
Treatments:
Bismuth subsalicylate
Psyllium
Criteria
Inclusion Criteria:

- Planning to be admitted to the hospital to undergo minimally-invasive urogynecologic
surgery at Strong Memorial Hospital.

Procedures may include:

- robot-assisted laparoscopic sacrocolpopexy

- sacrospinous ligament suspension

- uterosacral ligament suspension/paravaginal defect repair

- colpocleisis

- cystocele repair

Additional procedures may include:

- hysterectomy

- adnexectomy

- culdoplasty

- minimally invasive sling procedure (TVT or TOT)

- periurethral collagen injections

- enterocele repair

Exclusion Criteria:

- Planning to undergo laparotomy.

- Undergoing rectocele or perineocele repair as part of surgery.

- Taking Miralax, laxatives, enemas, or suppositories daily, at the time of enrollment.

- Presence of a colostomy.

- Chronic kidney disease

- Insulin-dependent diabetes mellitus

- Known cardiac disease

- Gastric ulcers

- Difficulty swallowing or esophageal stricture

- Persistent nausea and vomiting

- Signs and symptoms consistent with bowel obstruction